Point72 Asset Management
DSGN icon

Point72 Asset Management’s Design Therapeutics DSGN Stock Holding History

Point72 Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.2M Sell
2,366,453
-356,301
-13% -$4.44M 0.04% 603
2026
Q1 		$29M Sell
2,722,754
-2,649,250
-49% -$26.8M 0.04% 625
2025
Q4 		$50.4M Buy
5,372,004
+2,031,452
+61% +$15.9M 0.06% 403
2025
Q3 		$25.2M Buy
3,340,552
+1,533,334
+85% +$7.68M 0.04% 474
2025
Q2 		$6.09M Sell
1,807,218
-10,640
-0.6% -$39.8K 0.01% 902
2025
Q1 		$7.02M Sell
1,817,858
-38,892
-2% -$186K 0.02% 811
2024
Q4 		$11.5M Buy
1,856,750
+256,010
+16% +$1.48M 0.03% 643
2024
Q3 		$8.61M Buy
1,600,740
+609,939
+62% +$2.87M 0.02% 691
2024
Q2 		$3.32M Buy
990,801
+397,285
+67% +$1.55M 0.01% 960
2024
Q1 		$2.39M Buy
+593,516
New +$1.59M 0.01% 1203
2023
Q4 		– Sell
-1
Closed -$2 – 2308
2023
Q3 		$2 Sell
1
-5,348
-100% -$24.9K ﹤0.01% 2403
2023
Q2 		$33.7K Sell
5,349
-4,781
-47% -$29.3K ﹤0.01% 1694
2023
Q1 		$58.5K Buy
+10,130
New +$75.8K ﹤0.01% 1753

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

Point72 Asset Management's DSGN Position: Q2 2026 in Review

Point72 Asset Management reduced its Design Therapeutics (DSGN) stake by 13% in Q2 2026, selling an estimated $4.44M and leaving 2,366,453 shares worth $34.2M. The position accounts for 0.04% of the portfolio, ranked #603.

Point72 Asset Management first reported a position in DSGN in Q1 2023 and has held it in 13 quarters since. The position peaked at $50.4M in Q4 2025. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Point72 Asset Management held 2,366,453 shares of Design Therapeutics worth $34.2M as of Q2 2026.
  • Point72 Asset Management sold 356,301 Design Therapeutics shares in Q2 2026, an estimated $4.44M.
  • Design Therapeutics made up 0.04% of Point72 Asset Management's portfolio in Q2 2026, its #603 holding.
  • Point72 Asset Management first reported a position in Design Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Point72 Asset Management's Design Therapeutics position peaked at $50.4M in Q4 2025.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.